MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.17
+0.46
+1.60%
Pre Market: 29.17 0 0.00% 08:19 05/07 EDT
OPEN
28.92
PREV CLOSE
28.71
HIGH
29.63
LOW
28.22
VOLUME
10
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
24.85
MARKET CAP
4.13B
P/E (TTM)
-15.9643
1D
5D
1M
3M
1Y
5Y
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
Zacks · 21h ago
Allogene Therapeutics (ALLO) Gets a Hold Rating from Raymond James
Raymond James analyst Dane Leone maintained a Hold rating on Allogene Therapeutics (ALLO) yesterday. The company's shares closed last Thursday at $28.89,
SmarterAnalyst · 22h ago
Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat
Zacks.com · 1d ago
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
Zacks.com · 1d ago
Allogene Therapeutics (ALLO) Gets a Buy Rating from Oppenheimer
In a report released today, Mark Breidenbach from Oppenheimer assigned a Buy rating to Allogene Therapeutics (ALLO), with a price target of $52.00. The
SmarterAnalyst · 1d ago
William Blair Thinks Allogene Therapeutics’ Stock is Going to Recover
William Blair analyst Raju Prasad reiterated a Buy rating on Allogene Therapeutics (ALLO) yesterday. The company's shares closed last Wednesday at $28.71,
SmarterAnalyst · 1d ago
DJ Allogene Therapeutics, Inc. CEO David Chang on Q1 2021 Results -- Earnings Call Transcript >ALLO
Dow Jones · 1d ago
Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates
Zacks.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALLO. Analyze the recent business situations of Allogene Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALLO stock price target is 49.00 with a high estimate of 71.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 220
Institutional Holdings: 94.04M
% Owned: 66.47%
Shares Outstanding: 141.49M
TypeInstitutionsShares
Increased
72
4.70M
New
22
3.25M
Decreased
43
2.28M
Sold Out
19
1.39M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Executive Director
Arie Belldegrun
President/Chief Executive Officer/Co-Founder/Director
David Chang
Co-Founder/Director
Joshua Kazam
Chief Financial Officer/Primary Contact
Eric Schmidt
Executive Vice President
Rafael Amado
Chief Technology Officer
Alison Moore
Chief Compliance Officer/General Counsel
Veer Bhavnagri
Lead Director/Independent Director
David Bonderman
Independent Director
John DeYoung
Independent Director
Franz Humer
Independent Director
Deborah Messemer
Independent Director
Todd Sisitsky
Independent Director
Owen Witte
No Data
About ALLO
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Webull offers kinds of Allogene Therapeutics Inc stock information, including NASDAQ:ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.